101 related articles for article (PubMed ID: 17079466)
1. Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications.
Desai SJ; Ma AH; Tepper CG; Chen HW; Kung HJ
Cancer Res; 2006 Nov; 66(21):10449-59. PubMed ID: 17079466
[TBL] [Abstract][Full Text] [Related]
2. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
3. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.
Lee LF; Guan J; Qiu Y; Kung HJ
Mol Cell Biol; 2001 Dec; 21(24):8385-97. PubMed ID: 11713275
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
6. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
7. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor.
Kraus S; Gioeli D; Vomastek T; Gordon V; Weber MJ
Cancer Res; 2006 Nov; 66(22):11047-54. PubMed ID: 17108144
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic activation of androgen receptor.
Kung HJ; Evans CP
Urol Oncol; 2009; 27(1):48-52. PubMed ID: 19111798
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial androgen receptor targeted therapy for prostate cancer.
Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
[TBL] [Abstract][Full Text] [Related]
10. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
[TBL] [Abstract][Full Text] [Related]
11. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity.
Zoubeidi A; Zardan A; Beraldi E; Fazli L; Sowery R; Rennie P; Nelson C; Gleave M
Cancer Res; 2007 Nov; 67(21):10455-65. PubMed ID: 17974989
[TBL] [Abstract][Full Text] [Related]
12. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
13. 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways.
Chintharlapalli S; Papineni S; Safe S
Mol Pharmacol; 2007 Feb; 71(2):558-69. PubMed ID: 17093136
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
15. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
Heemers HV; Regan KM; Dehm SM; Tindall DJ
Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004
[TBL] [Abstract][Full Text] [Related]
16. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
17. Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.
Suh JH; Gong EY; Kim JB; Lee IK; Choi HS; Lee K
Mol Cancer Res; 2008 Feb; 6(2):314-24. PubMed ID: 18245227
[TBL] [Abstract][Full Text] [Related]
18. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract][Full Text] [Related]
19. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway.
Yan J; Yu CT; Ozen M; Ittmann M; Tsai SY; Tsai MJ
Cancer Res; 2006 Nov; 66(22):11039-46. PubMed ID: 17108143
[TBL] [Abstract][Full Text] [Related]
20. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
